Drug Approval | May 13, 2024
Zydus receives final approval from USFDA for Dexamethasone Tablets
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Global Phase-3 study initiation expected in the second half of 2024
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Subscribe To Our Newsletter & Stay Updated
